Biomedical Technology News
-
Innovating Biomedical Engineering: Installation at the University of Strathclyde
Stephen Haywood, Test and Installation Engineer at Hiden Analytical, recently installed an EQP Mass and Energy Analyser at the University of Strathclyde’s Biomedical Engineering Department. This revolutionary tool will accelerate their research on prosthetic ...
-
First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
-
Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases. The first is a $5 million grant from the Bill & Melinda Gates Foundation for a second Phase 2 study of an improved anti-campylobacter therapeutic, ...
-
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
-
Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. Mariola ...
By Ardigen
-
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
Ardigen, one of the world’s leading artificial intelligence (AI) companies advancing precision medicine, has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise. The consortium of 10 leading pharmaceutical companies and two non-profit research organizations including the Broad Institute of MIT ...
By Ardigen
-
Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...
By Ardigen
-
CD Bioparticles Introduces Hydrophilic Coatings for Medical Applications
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced hydrophilic coatings and related services for medical applications, which can be used within interventional medical devices of the cardiovascular, circulatory, nervous, urinary, and vascular system. Functional medical coatings are a class of interface materials applied to the ...
-
CD Bioparticles Launches NIR-Quantum Dots for Biomedical Imaging
With years of experience in the pharmaceutical and life science sector, CD Bioparticles launched a range of near-infra-red (NIR) quantum dots that exhibit excellent optical properties and biocompatibility for biomedical imaging. Currently, CD Bioparticles has successfully synthesized a variety of NIR quantum dots, including PbS/CdS, PbS, PbSe, Ag2S, CuInS/ZnS, and CdTe/CdSe/ZnS. Quantum points ...
-
Prof. Krestin Joins Fluidda’S Board of Directors
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
By Fluidda
-
Creative Proteomics Has Optimized Pre-treatments and Assays for Different Types of Vitamins
Metabolomics, a subdivision of Creative Proteomics, is dedicated to providing metabolomics services based on cutting-edge LC-MS technology for biomedical research institutions, biotechnology companies, and pharmaceutical companies. Creative Proteomics has developed highly sensitive, selective and accurate LC/MS/MS analytical solutions for the identification and quantification of vitamins in ...
-
Prof. Dr. med. Michael Schmitt, MHBA has joined Ardigen`s Scientific Board to support the development of AI platforms for cell therapy discovery
Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Prof. Dr. Michael Schmitt, MHBA, has joined the company’s Scientific Advisory Board. His knowledge and experience will support work on artificial intelligence-based platforms, dedicated to accelerating and optimizing the discovery of novel cell ...
By Ardigen
-
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors. Arteriovenous malformations (AVMs) occur when capillaries, veins, and ...
-
Berkshire Biomedical Awarded NIH Research Grant to Support Continued Development of the COPA System for Automated at Home Methadone Administration
Berkshire Biomedical Corporation ("Berkshire" or "the Company"), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced that it has been awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of Health's (NIH) National ...
-
ConcertAI’s TeraRecon Accelerates Multi-Specialty Advanced Visualization Capabilities with the Launch of Intuition 4.6
TeraRecon, a ConcertAI company and a leader in advanced medical visualization to improve patient care, today announced the global launch of Intuition 4.6 at the European Congress of Radiology in Vienna, Austria. "Intuition 4.6 brings a comprehensive set of improvements to our award-winning AV software solution, many of which came as a direct result with collaborations with practitioners," said ...
-
TeraRecon Announces DocPanel Signs Contract for Intuition Titanium, Reaffirming its Cardiothoracic Imaging Service Commitment
TeraRecon, a ConcertAI company and a leader in advanced medical visualization using AI to improve patient care, today announced U.S.-based DocPanel, the world’s first radiology marketplace offering access to over 500 fellowship trained radiologists available for radiological reads, second opinions, and educational consults, has signed a contract for TeraRecon’s advanced visualization ...
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of Directors Alexis Borisy, ModeX Lead ...
-
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable embolic therapies, announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in collaboration ...
-
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies
TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at the Creative Lab for Innovation Kobe (CLIK). Incorporated in Bordeaux, France, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you